rss
J Clin Pathol 2006;59:721-724 doi:10.1136/jcp.2005.029975
  • Original article

Topoisomerase II-α expression increases with increasing Gleason score and with hormone insensitivity in prostate carcinoma

  1. C Hughes1,
  2. A Murphy2,
  3. C Martin3,
  4. E Fox4,
  5. M Ring3,
  6. O Sheils3,
  7. B Loftus2,
  8. J O’Leary3
  1. 1Histopathology Department, John Radcliffe Hospital, Headington, Oxford, UK
  2. 2Department of Pathology, Adelaide and Meath Hospital Incorporating the National Children’s Hospital, and Trinity College, Dublin, Ireland
  3. 3Department of Pathology, Coombe Women’s Hospital, and Trinity College Dublin
  4. 4Department of Pathology, Conway Institute of Biomolecular and Biomedical Research, University College Dublin, Dublin
  1. Correspondence to:
 Dr C Hughes
 Histopathology Department, John Radcliffe Hospital, Headington, Oxford OX3 9DZ, UK; caroline.hughes{at}orh.nhs.uk
  • Accepted 20 December 2005
  • Published Online First 23 March 2006

Abstract

Aim: To investigate and compare topoisomerase II-α expression in benign prostatic hyperplasia (BPH), prostate cancer of varying Gleason scores and hormone-insensitive prostate cancer.

Methods: The immunohistochemical expression of topoisomerase II-α antibody in the above-mentioned diagnostic categories was investigated and compared.

Results: Increased expression of topoisomerase II-α was seen in the prostate cancers of Gleason scores 7 and 8–10 (p = 0.000) compared with prostate cancers of Gleason score 6 and BPH (p = 0.245). Statistically significant differences were found in the topoisomerase II-α gene expression between prostate cancers categorised by Gleason Score. Also, increased expression of topoisomerase II-α was seen in the known hormone-resistant prostate carcinomas compared with prostate cancers with no hormone treatment in the subgroup with Gleason scores 8–10, which approached statistical significance (p = 0.081). No statistically significant difference was observed in topoisomerase II-α expression between the groups with BPH and prostate carcinoma of Gleason score 6 (p = 0.245).

Conclusion: Topoisomerase II-α expression was found to increase with the known prognostic marker Gleason score and with hormone insensitivity. Objective evidence is provided for clinical trials with drugs targeting topoisomerase II-α to be targeted to patients with prostate cancers of Gleason Score >6 and, in particular, prostate cancers of Gleason Scores 8–10.

Footnotes

    This Article

    1. Abstract
    2. Full text
    3. PDF
    4. All versions of this article:
      1. jcp.2005.029975v1
      2. 59/7/721 most recent

    Responses

    1. Submit a response
    2. No responses published

    Register for free content


    Free trial
    Individuals may register for a free 60 day online trial to all content.

    Free archive
    The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.

    Don't forget to sign up for content alerts so you keep up to date with all the articles as they ar